Skip to main content
. 2021 Feb 26;7:38. doi: 10.1038/s41420-021-00421-3

Fig. 5. Targeting SOAT1 synergizes with nystatin in suppressing the viability of colon cancer cells in vitro.

Fig. 5

A SW1116 and SW480 were treated with control siRNA or siSOAT1 in the presence or absence of nystatin (20 μM). Cell proliferation activity was detected by CCK-8 after 72 h. B SW1116 and SW480 were treated with DMSO or avasimibe (10 μM) in the presence or absence of nystatin (20 μM). Cell proliferation activity was detected by CCK-8 after 72 h. C SW1116 and SW480 were incubated with DMSO or avasimibe (10 μM) in the presence or absence of nystatin (20 μM) for 5 d, respectively. The cell proliferation ability was detected by the colony formation assay. D SW1116 and SW480 were treated with nystatin (10–30 μM) for 16 h. E SW1116 and SW480 were transfected with negative control siRNA or SOAT1 siRNA for 48 h, respectively. The cells were then incubated with DMSO or nystatin (20 μM) for 16 h. F SW1116 and SW480 were incubated with DMSO or avasimbie (10 μM) in the presence or absence of nystatin (20 μM) for 16 h, respectively. The expression of proteins was detected by Western blot.